Prescription medicine
Erenumab Brand names: Aimovig
Erenumab (Aimovig) is a prescription medicine. No generic is listed; pharmacies paid $753.33 per mL (Aimovig 140 mg/mL autoinjector) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the erenumab FDA label on DailyMed (effective July 14, 2026); every erenumab label on DailyMed.
Highlights of the record
FDA label of July 14, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageAIMOVIG is indicated for the preventive treatment of migraine in adults.
Forms and strengths
- 70 mg/ml
- 140 mg/ml
Injection (solution); injection.
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $753.33 per mL Aimovig 140 mg/mL autoinjector
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 54,778 through July 30, 2026
What is erenumab used for?
From the label: indications and usageAIMOVIG is indicated for the preventive treatment of migraine in adults. AIMOVIG is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults.
Conditions named in the indications of erenumab's FDA labels, with every medicine labeled for each:
Source: FDA drug label (AIMOVIG), Amgen, Inc, effective July 14, 2026 (SPL set b998ed05-94b0-47fd-b28f-cddd1e128fd8), via openFDA; the full label on DailyMed
Is there a generic for erenumab (Aimovig)?
No generic erenumab is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for erenumab (Aimovig)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $753.33 per mL (Aimovig 140 mg/mL autoinjector), up 2% from $739.17 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Aimovig 140 mg/mL autoinjector (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Aimovig 140 mg/mL autoinjector | Brand | $753.33 per mL | n/a | +2% |
| Aimovig 70 mg/mL autoinjector | Brand | $753.57 per mL | n/a | +2% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for erenumab?
The FDA Adverse Event Reporting System holds 54,778 reports that list erenumab among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 2,964 are coded as a death and 4,458 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as erenumab?
4 other medicines are given the same way (subcutaneous) and in the same FDA class as erenumab or labeled mainly for the same use (migraine), the same class first. Migraine lists all 27 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Sumatriptan | Migraine | 20 labelers | $14.93 per mL 6 mg/0.5 mL vial | No current entry |
| Galcanezumab | Migraine | none listed | $734.28 per mL 120 mg/mL pen | No current entry |
| Fremanezumab | Migraine | none listed | $508.17 per mL 225 mg/1.5 mL autoinject | No current entry |
| Dihydroergotamine | Migraine | none listed | n/a | No current entry |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to erenumab
- 4 medicines for the same use
- Erenumab side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other